Chinese Academy of

This program combines ursodeoxycholic acid with total glucosides of paeony for the treatment of hepatitis, specifically targeting cases with primary biliary cholangitis (PBC) features combined with autoimmune hepatitis (AIH) characteristics. The sponsor is Xiyuan Hospital of China Academy of Chinese Medical Sciences, a research institution within China's traditional medicine framework. The program has achieved approved status as of the latest milestone dated 24 March 2021. The combination represents an integration of bile acid therapy (ursodeoxycholic acid) with a traditional Chinese medicine component (paeony glucosides), reflecting a dual-mechanism approach to hepatic inflammation and cholestasis. The program is currently active and supported by clinical trial data registered under NCT04618575. No commercial partner or licensing arrangement has been disclosed. Regulatory approval appears to have been granted in China, though specific approval details and dates remain undisclosed in available sources.

Hepatitis with overlapping PBC and AIH features represents a challenging clinical subset with limited therapeutic options. Patients with PBC-AIH overlap syndrome typically require combination therapy and often show suboptimal response to monotherapy. The unmet medical need is substantial: standard ursodeoxycholic acid monotherapy achieves biochemical response in only 40–60% of PBC patients, and AIH overlap cases are even more refractory. This combination therapy addresses both cholestatic and autoimmune components simultaneously, potentially improving response rates and reducing disease progression. The market relevance extends across Asia, where both PBC and traditional medicine-based therapeutics have significant adoption. Competitive positioning is notable: approved therapies like OCALIVA (obeticholic acid), LIVMARLI (maralixibat), BYLVAY (odevixibat), and IQIRVO (sofosbuvir/velpatasvir/voxilaprevir) target specific mechanisms but do not combine bile acid therapy with immunomodulatory herbal components. The patient population for PBC-AIH overlap is estimated at 5–10% of all PBC cases, representing several thousand patients globally. Commercial significance is moderate to high in Asian markets where regulatory pathways for traditional medicine combinations are established and reimbursement for combination therapies is increasingly available.

Drug Class: Combination small-molecule therapy combining a bile acid (ursodeoxycholic acid) with a botanical extract (total glucosides of paeony).

Modality: Small-molecule oral formulation.

Route of Administration: Oral.

Mechanism of Action: Ursodeoxycholic acid functions as a hydrophilic bile acid that reduces hepatotoxic bile acid concentration, improves bile flow, and has anti-inflammatory properties. Total glucosides of paeony (derived from Paeonia lactiflora) possess immunomodulatory and anti-inflammatory effects, potentially suppressing Th17 cell differentiation and reducing autoimmune hepatic inflammation.

Target: Dual targeting of cholestatic injury (via bile acid homeostasis) and autoimmune-mediated hepatic inflammation.

Related Therapies: Ursodeoxycholic acid is a first-line therapy for PBC; obeticholic acid (OCALIVA) is a farnesoid X receptor (FXR) agonist approved for PBC; maralixibat (LIVMARLI) is an apical sodium-dependent bile acid transporter (ASBT) inhibitor; odevixibat (BYLVAY) is another ASBT inhibitor for progressive familial intrahepatic cholestasis.

Patent Status: Not yet disclosed.

FDA (United States): Not yet disclosed; no FDA approval pathway or status information available in the facts.

EMA (European Union): Not yet disclosed; no EMA approval pathway or status information available in the facts. Note: The facts reference ORPHACOL (cholic acid) with EMA approvals by Retrophin Europe Ltd and Theravia, but this is a separate comparator drug, not the ursodeoxycholic acid + paeony combination.

NMPA (China): Program status is listed as approved as of 24 March 2021; however, specific NMPA approval date, application number, and regulatory classification are not disclosed.

PMDA (Japan): Not yet disclosed.

Regulatory Status Summary: The program is confirmed as approved, likely in China given the sponsor (Xiyuan Hospital of China Academy of Chinese Medical Sciences), but formal approval documentation, regulatory authority confirmation, and approval date remain undisclosed. No international regulatory filings or approvals have been disclosed.

Strategic Positioning: The program represents a deliberate strategy by a Chinese traditional medicine institution to validate herbal-conventional drug combinations within a regulated framework. Approval status as of March 2021 suggests successful navigation of China's regulatory pathway for traditional medicine combinations, but lack of published trial data limits scientific credibility in international markets.

Competitive Implications: The combination therapy does not appear to directly compete with modern FXR agonists (OCALIVA) or ASBT inhibitors (LIVMARLI, BYLVAY) on mechanism of action. Instead, it targets a niche market segment in Asia where traditional medicine integration is valued. However, without comparative efficacy data, market penetration outside China is unlikely. The program's strength lies in potential cost advantage (paeony glucosides are inexpensive) and cultural acceptance in Asia.

Clinical Evidence Gap: The single registered trial (NCT04618575) has not published results. The absence of peer-reviewed efficacy and safety data is a significant limitation for international adoption and physician confidence. Publication of trial results would be a critical catalyst for program visibility and competitive positioning.

Future Catalysts: Publication of NCT04618575 results; regulatory approval in additional Asian markets (Japan, South Korea); head-to-head comparative efficacy studies versus OCALIVA or ASBT inhibitors; expansion of indication beyond PBC-AIH overlap to broader hepatitis populations; partnership with international pharmaceutical companies for distribution and development.

Market Opportunity: PBC-AIH overlap syndrome affects an estimated 5–10% of PBC patients globally. In China, where the program is approved, this represents a patient population in the tens of thousands. However, without international regulatory approvals or published efficacy data, commercial potential remains primarily regional.